MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2026-03-31.

Income Overview

Net Income
-$12,824K
EPS
-$0.54
Unit: Thousand (K) dollars

Income Statement
2026-03-31
2025-12-31
2025-09-30
2025-06-30
Research and development
1,607 2,050* 2,964 1,750
General and administrative
6,830 6,010* 4,378 5,213
Total operating expenses
8,437 8,060 7,342 6,963
Loss from operations
-8,437 -8,060* -7,342 -6,963
Interest income
394 362* 279 155
Interest expense
-29* 15 13
Change in fair value of warrant liability
4,780 141* -1,067 -374
Total other income (expenses)
-4,386 192* 1,331 516
Net income (loss)
-12,823 -7,869* -6,011 -6,447
Dividend to series b-1 preferred stockholders
---0
Net income attributable to participating securities
---0
Unrealized loss on marketable securities, net
-1 0* --
Net loss attributable to common stockholders
---6,011 -6,447
Net comprehensive income (loss)
-12,824 -7,869 --
Basic EPS
-0.54 -0.455 -0.33 -0.52
Diluted EPS
-0.54 -0.455 -0.33 -0.52
Basic Average Shares
23,908,153 17,293,180 18,065,389 12,302,059
Diluted Average Shares
23,908,153 17,293,180 18,065,389 12,302,059
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Income Statement

DownloadDownload image
Net comprehensiveincome (loss)-$12,824K Net income (loss)-$12,823K Unrealized loss onmarketable securities, net-$1K Loss from operations-$8,437K Total other income(expenses)-$4,386K Interest income$394K Total operatingexpenses$8,437K Change in fair value ofwarrant liability$4,780K General andadministrative$6,830K Research and development$1,607K

Unicycive Therapeutics, Inc. (UNCY)

Unicycive Therapeutics, Inc. (UNCY)